Results 261 to 270 of about 194,414 (305)

Amonafide Targeting NTSR1-PI3K/AKT/mTOR Signaling Attenuates Vascular Remodeling in Pulmonary Arterial Hypertension. [PDF]

J Am Heart Assoc
Zhu YJ, Kou JJ, Bo YC, Zhang MJ, Fan X, Zhao LL, Yan Y, Zhang HD, Wu WH, Yuan P, Liu Y, Shi JZ, Pang XB, He YY.   +13 more
europepmc   +1 more source

Reduced Circulating HIF-1α, HIF-2α, HIF-3α, and VHL Levels in Patients With Pulmonary Arterial Hypertension. [PDF]

Pulm Circ
Kan H, Alsancak Y, Uyaner Kan M, Göktaş E, Çelik M, Gürbüz AS, Düzenli MA.   +6 more
europepmc   +1 more source

Targeting the Hippo pathway in pulmonary arterial hypertension: emerging pharmacological strategies. [PDF]

J Hypertens
Zheng D, Guo Y.
europepmc   +1 more source

Transitioning From Oral to Intravenous Treprostinil in Pulmonary Arterial Hypertension: A Case Report. [PDF]

Clin Case Rep
Cummings AM, Konkol SB, Mihalek AD, Roth ME.   +3 more
europepmc   +1 more source

Methamphetamine-Associated Pulmonary Arterial Hypertension: Impact, Mechanisms, and a Framework for Management. [PDF]

Pulm Circ
Sood N, Weerasekare J, Zhyvylo I, Goncharova EA, De Marco T.   +4 more
europepmc   +1 more source

Unusual Cutaneous and Lymphatic Findings in an Adult Patient

JEADV Clinical Practice, EarlyView.
Sarah Preis, Mara Hubbuch, Susanne Annette Steimle‐Grauer, Tilo Biedermann, Oana‐Diana Persa   +4 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pulmonary Arterial Hypertension

New England Journal of Medicine, 2004
Harrison W Farber, Joseph Loscalzo, Jacob Joseph   +2 more
exaly   +3 more sources

Pulmonary arterial hypertension

Medicina Clínica (English Edition), 2022
Pulmonary arterial hypertension (PAH) is a rare disease characterized by adverse remodeling of the arterial tree leading to increased vascular resistance with subsequent increase in right ventricular afterload and eventual development of heart failure.
Raquel, Luna-López, Alicia, Ruiz Martín, Pilar, Escribano Subías   +2 more
openaire   +2 more sources

Pulmonary arterial hypertension

La Presse Médicale, 2023
Pulmonary arterial hypertension (PAH) is a rare and progressive disease characterised by remodelling of the pulmonary arteries and progressive narrowing of the pulmonary vasculature. This leads to a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure and, if left untreated, to right ventricular failure and death.
Athénaïs Boucly, Christian Gerges, Laurent Savale, Xavier Jaïs, Mitja Jevnikar, David Montani, Olivier Sitbon, Marc Humbert   +7 more
openaire   +2 more sources